The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012 -- during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide (TAF) and present evidence about when and how to stop antiviral therapy.
Hepatitis C patients treated with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a set of studies presented at the EASL International Liver Congress this week in Amsterdam.
HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.
Participants at a Community HIV Cure Research Workshop on February 12, in advance of the Conference on Retroviruses and Opportunistic Infections in Seattle, held a "birthday" party for Timothy Ray Brown -- formerly known as the Berlin Patient -- to celebrate 10 years since the bone marrow transplant that would lead to the only known cure for HIV.